Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Source: Aerie

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases, announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on netarsudil to potential new product candidates such as the new class of corticosteroid anti-inflammatories.

The following posters are independent research and not sponsored by Aerie Pharmaceuticals:

  • Title: Effect of the rho-kinase inhibitor Netarsudil on established corneal neovascularization in a PAX-6 knockout mouse model
    • Date: Sunday, May 2, 2021
    • Time: 9:00 – 10:45 a.m. Eastern Time
    • Presenter: Timothy Janetos, MD, Northwestern University Feinberg School of Medicine
  • Title: Adjunctive Use of Netarsudil in Refractory Glaucoma: 1-year Retrospective Analysis
    • Date: Monday, May 3, 2021
    • Time: 11:15 a.m. – 1:00 p.m. Eastern Time
    • Presenter: Vladislav Bekerman, MD, Rutgers University Medical School Department of Ophthalmology & Visual Science
  • Title: Efficacy of Netarsudil in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy
    • Date: Monday, May 3, 2021
    • Time: 11:15 a.m. – 1:00 p.m. Eastern Time
    • Presenter: Reza Kianian, University of California Los Angeles David Geffen School of Medicine
  • Title: Pragmatic usage of Netarsudil: A Retrospective Chart Review from a Tertiary Care Center
    • Date: Tuesday, May 4, 2021
    • Time: 10:15 a.m. – 12:00 noon Eastern Time
    • Presenter: Nate Goergen, PhD, University of Nebraska Medical Center
  • Title: Effect of Rho-kinase Inhibition on a Patient-Derived Model of Proliferative Vitreoretinopathy
    • Date: Wednesday, May 5, 2021
    • Time: 9:00 – 10:45 a.m. Eastern Time
    • Presenter: Leslie Ramos, Schepens Eye Research Institute of Massachusetts Eye and Ear
  • Title: Efficacy of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
    • Date: Wednesday, May 5, 2021
    • Time: 2:45 – 4:30 p.m. Eastern Time
    • Presenter: Natacha Villega, MD, Stanford University

The following posters are sponsored by Aerie Pharmaceuticals:

  • Title: Novel Corticosteroid Class Reduces Inflammation and Lowers IOP in Animal Models
    • Date: Wednesday, May 5, 2021
    • Time: 2:45 – 4:30 p.m. Eastern Time
    • First author: Kevin Carbajal, PhD, Aerie Pharmaceuticals
  • Title: Ocular Pharmacokinetics of a Novel Class of Corticosteroids with ROCK Inhibitory Activity and Potential for Reduced Steroid-Associated Risks
    • Date: Wednesday, May 5, 2021
    • Time: 2:45 – 4:30 p.m. Eastern Time
    • First author: Maria Zaretskaia, MD, Aerie Pharmaceuticals
  • Title: The Synthesis and Testing of Rho Kinase Inhibitors Reversibly Coupled to Corticosteroids for the Treatment of Ocular Inflammatory Diseases
    • Date: Friday, May 7, 2021
    • Time: 2:15 – 4:00 p.m. Eastern Time
    • First author: Mitchell deLong, PhD, Aerie Pharmaceuticals

In addition, Casey Kopczynski, Ph.D., Aerie’s Chief Scientific Officer, will participate in a Mini-Symposium entitled “Rho Kinase Inhibitors, a New Class of Treatment for Glaucoma and Corneal Disease” that will take place on Wednesday, May 5, 2021, from 5:00 – 6:45 p.m. Eastern Time. His podium presentation entitled “Clinical experience with netarsudil, a new class of glaucoma drug targeting trabecular outflow” will be from 5:07 – 5:20 p.m. Eastern Time.

Related Content